ScreenerHero

BNTXBioNTech SE

NAS · US · Healthcare · Biotechnology · biontech.de
116.57USDMkt Cap: 29.28B $P/E: —

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also devel…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
CORT
Corcept Therapeutics Incorporated
$13.22BUSDP/E 271.7

Key Statistics

Company
Market Cap29.28B $
Enterprise Value16.14B $
Revenue (TTM)2.65B $
Gross Profit2.23B $
Net Income (TTM)-1.14B $
Revenue/Share10.69 USD
Last Price116.57 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7.8K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS09075V1026
Valuation
P/E (Trailing)—
P/E (Forward)-20.52
PEG0.05
EV/EBITDA-11.69
EV/Revenue6.09
P/S11.05
P/B1.42
EPS (TTM)-7.83
EPS (Forward)-5.68
52W Range
110.8960% of range120.30
52W High120.30 USD
52W Low110.89 USD
Profitability
Gross Margin77.64%
Oper. Margin-806.63%
EBITDA Margin-52.11%
Profit Margin-39.59%
ROE-5.91%
ROA-5.17%
Growth
Revenue Growth-59.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF456.00M $
CapEx (TTM)749.00M $
FCF Margin-9.42%
FCF Yield-0.85%
Net Debt-13.15B $
Net Debt/EBITDA9.52
Balance Sheet
Debt/Equity0.01
Current Ratio7.85
Quick Ratio7.03
Book Value/Sh81.83 USD
Cash/Share53.60 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 2, 2022
Pay DateJun 17, 2022
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)121.60 USD
Upside (mean)+4.3%
Target Range76.20 USD – 145.36 USD
$76.20+4.3% to mean$145.36
# Analysts20
Ownership
Shares Out.251.20M
Float108.42M
Insiders57.51%
Institutions20.37%
Short Interest
Short Ratio3.2d
Short % Float3.69%
Short % Out.0.98%
Shares Short2.47M
Short (prev mo.)2.32M
Technical
SMA 5093.26 (+25.0%)
SMA 20097.58 (+19.5%)
Beta1.28
S&P 52W Chg19.18%
Avg Vol (30d)2.96M
Avg Vol (10d)2.02M
Technical Indicators
RSI (14)79.2
MACD4.1769
MACD Signal1.6045
MACD Hist.+2.5725
BB Upper111.22 USD
BB Middle95.45 USD
BB Lower79.69 USD
BB Width33.03%
ATR (14)4.513 USD
Vol Ratio (20d)1.98x